NEWS & EVENTS
The New York Times features NIBIB grantees Bob Langer and Ralph Weissleder as being “on the front lines of turning discoveries made in the lab into a range of drugs and drug deliver systems. Without this kind of technology transfer, the thinking goes, scientific discoveries might well sit on the shelf, stifling innovation.” Read the full article from The New York Times.
NIBIB-funded research has resulted in a new spectrum of voltage-sensitive dyes (VSDs) that improves optical imaging of brain and heart electrical activity. Fluorinated hemicyanine dyes provide spectral compatibility with newly available optical technologies, offering better photostability and improving the signal to noise ratio (S:N) of the optically recorded voltage activity in cells, tissues, and organs. Read the full article from Proceedings of the National Academy of Sciences.
In a mouse model of multiple sclerosis (MS), NIBIB-funded researchers Stephen Miller and Lonnie Shea at Northwestern University have developed innovative biotechnology to selectively inhibit the part of the immune system responsible for attacking myelin–the insulating material that encases nerve fibers and facilitates electrical communication between brain cells. Read the full article from Northwestern University.
Identifying new compounds to treat heart disease, cancer, or other inflammatory and immune-related disorders may get easier using a precisely tailored application of solid state nuclear magnetic resonance (NMR) spectroscopy–which can reveal a protein’s entire 3-D structure within its natural surroundings.
A team of researchers including NIBIB investigator Kit Lam at the University of California Davis has discovered a new class of nanoparticles capable of packaging a diverse array of drugs. Research findings demonstrate structural and dynamic changes within nanoparticles during interaction with blood proteins which will result in better designed nanomedicines that will be therapeutically more efficacious. Read the full article from ACSNano.